Xenon Pharmaceuticals

Xenon Pharmaceuticals: Azetukalner Nears Late-Stage Development in Neurological Therapeutics

We at Xenon Pharmaceuticals focus on new treatments for brain disorders. Our main drug, azetukalner, opens certain channels in the brain. It targets epilepsy and depression.

Continue Reading on Meyka

This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.

Read Full Article →

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *